1. |
Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the global burden of disease study 2013. Lancet, 2015, 386(9995): 743-800.
|
2. |
Almirall J, Bolibar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J, 2000, 15(4): 757-763.
|
3. |
Tichopad A, Roberts C, Gembula I, et al. Clinical and economic burden of community-acquired pneumonia among adults in the czech republic, hungary, poland and slovakia. PloS One, 2013, 8(8): e71375.
|
4. |
Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet, 2015, 386(9998): 1097-1108.
|
5. |
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infec Dis, 2007, 44(Suppl 2): S27-72.
|
6. |
Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: Update 2009. Thorax, 2009, 64(Suppl 3): iii1-55.
|
7. |
中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南 (2016 年版). 中华结核和呼吸杂志, 2016, 39(4): 253-279.
|
8. |
Povoa P. Serum markers in community-acquired pneumonia and ventilator-associated pneumonia. Curr Opin Infect Dis, 2008, 21(2): 157-162.
|
9. |
Christ-Crain M, Opal SM. Clinical review: The role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care, 2010, 14(1): 203.
|
10. |
Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J, 2007, 30(3): 556-573.
|
11. |
Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care, 2006, 10(3): R96.
|
12. |
Magrini L, Gagliano G, Travaglino F, et al. Comparison between white blood cell count, procalcitonin and C reactive protein as diagnostic and prognostic biomarkers of infection or sepsis in patients presenting to emergency department. Clin Chem Lab Med, 2014, 52(10): 1465-1472.
|
13. |
李维勤, 黎介涛, 顾军, 等. 腹腔感染后低白蛋白血症的分子机理和防治实验研究. 中华外科杂志, 1997, 35(2): 100-103.
|
14. |
Lee JH, Kim J, Kim K, et al. Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. J Crit Care, 2011, 26(3): 287-294.
|
15. |
Viasus D, Garcia-Vidal C, Simonetti A, et al. Prognostic value of serum albumin levels in hospitalized adults with community-acquired pneumonia. J Infect, 2013, 66(5): 415-423.
|
16. |
Lemeshow S, Hosmer DW. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol, 1982, 115(1): 92-106.
|
17. |
Hanley JA, Mcneil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology, 1983, 148(3): 839-843.
|
18. |
Song JH, Oh WS, Kang CI, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in asian countries: a prospective study by the asian network for surveillance of resistant pathogens. Int J Antimicrob Agents, 2008, 31(2): 107-114.
|
19. |
Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA, 1996, 275(2): 134-141.
|
20. |
Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia: systematic review and meta-analysis. Thorax, 2010, 65(10): 878-883.
|
21. |
Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J, 2008, 31(2): 349-355.
|
22. |
Zobel K, Martus P, Pletz MW, et al. Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ. BMC Pulm Med, 2012, 12: 6.
|
23. |
Christ-Crain M, Breidthardt T, Stolz D, et al. Use of b-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med, 2008, 264(2): 166-176.
|
24. |
Kruger S, Papassotiriou J, Marre R, et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med, 2007, 33(12): 2069-2078.
|
25. |
Almirall J, Bolibar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest, 2004, 125(4): 1335-1342.
|
26. |
Chalmers JD, Singanayagam A, Scally C, et al. Admission o-dimer can identify low-risk patients with community-acquired pneumonia. Ann Emerg Med, 2009, 53(5): 633-638.
|